Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA
ORIA was delisted on the 28th of April, 2023.
49 hedge funds and large institutions have $145M invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 9 closing their positions.
4% less capital invested
Capital invested by funds: $151M → $145M (-$6.25M)
6% less funds holding
Funds holding: 52 → 49 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$9.41M |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$9.17M |
| 3 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
+$5.38M |
| 4 |
MC
Meteora Capital
Boca Raton,
Florida
|
+$3.72M |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KL
KIM LLC
Wichita,
Kansas
|
-$8.06M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$6.32M |
| 3 |
Millennium Management
New York
|
-$6.29M |
| 4 |
6CM
683 Capital Management
New York
|
-$5.08M |
| 5 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$2.67M |
ORIA Hedge Fund Activity: Q1 2023 in Review
49 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q1 2023, worth a combined $145M — down 4.1% from $151M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ORIA and 6 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was Westchester Capital Management (New York), adding an estimated $9.41M. The largest seller was KIM LLC, exiting entirely with an estimated $8.06M sold.
- 49 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q1 2023, down from 52 in Q4 2022.
- Funds reported $145M of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q1 2023, down 4.1% quarter-over-quarter.
- 6 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q1 2023 and 9 closed out, a net change of -3 holders.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share buyer in Q1 2023 was Westchester Capital Management (New York), an estimated $9.41M added.
- The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q1 2023 was KIM LLC, an estimated $8.06M sold.
Based on aggregated 13F filings for Q1 2023.